Bio-Path (BPTH) information about the pump from $73

Why did this happen?

"Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker"

Information about the stock trading this week

Bio-Path Holdings Inc (NASDAQ:BPTH) shares hit a new 52-week high during trading on Thursday . The company traded as high as $73.52 and last traded at $32.17, with a volume of 27769599 shares trading hands. The stock had previously closed at $12.02.Separately, ValuEngine lowered shares of Bio-Path from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.In related news, major shareholder Armistice Capital Master Fund sold 64,457 shares of the stock in a transaction dated Friday, January 18th. The shares were sold at an average price of $2.66, for a total value of $171,455.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.65% of the company’s stock.A hedge fund recently raised its stake in Bio-Path stock. Renaissance Technologies LLC grew its position in shares of Bio-Path Holdings Inc (NASDAQ:BPTH) by 45.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 198,730 shares of the company’s stock after buying an additional 62,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.75% of Bio-Path worth $296,000 as of its most recent filing with the Securities and Exchange Commission.
About Bio-Path (NASDAQ:BPTH) Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.